Recombinant vaccinia virus vaccine against the human melanoma antigen p97 for use in immunotherapy.

AUTOR(ES)

Estin, C D

RESUMO

We have constructed a recombinant vaccinia virus, v-p97NY, which expresses the human melanoma-associated glycoprotein p97. Immunization with v-p97NY could induce humoral and cell-mediated immunity to p97, including delayed-type hypersensitivity, in mice and in two of two monkeys (Macaca fascicularis). The fact that an immune response was induced also in monkeys is important because normal cells from monkeys, but not from mice, express a low level of cross-reactive p97. Mice immunized with v-p97NY rejected transplants of syngeneic mouse melanoma expressing p97. A rejection response could be detected also when immunization was started 2 days after tumor transplantation, irrespective of whether the transplanted cells grew subcutaneously or as lung metastases. Evidence was obtained that melanoma cells lacking p97 may be killed as "bystanders" at the site of an immune response to melanoma cells expressing p97.

Documentos Relacionados

• Characterization of a recombinant vaccinia virus expressing human melanoma-associated antigen p97.
• Primary structure of the human melanoma-associated antigen p97 (melanotransferrin) deduced from the mRNA sequence.
• Quantitative analysis of melanoma-associated antigen p97 in normal and neoplastic tissues.
• Melanoma, immune surveillance, and immunotherapy.
• Human cytomegalovirus UL97 kinase confers ganciclovir susceptibility to recombinant vaccinia virus.